Form 4: Pliant Therapeutics Director Receives Stock Option Grant
Director Equity Grant
Director Thomas A. McCourt was granted 70,000 stock options in Pliant Therapeutics, Inc. as part of standard equity compensation.
Summary
- Director Thomas A. McCourt received a grant of 70,000 stock options for Pliant Therapeutics (PLRX) common stock.
- The options have an exercise price of $1.14 per share.
- The grant date for these options is June 11, 2026.
- The options are set to expire on June 11, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Aligns director interests with long-term shareholder value through equity-based compensation.
Negatives
- The grant results in potential future dilution for existing shareholders upon exercise.
Risks
- Market volatility affecting the value of the underlying common stock.
- Vesting is contingent upon the director's continued service to the company.
Future Outlook
The options vest in quarterly increments starting October 1, 2026, through April 1, 2027, with the final portion vesting on the earlier of the one-year anniversary or the next annual meeting.
Management Comments
- No specific management commentary provided in this regulatory filing.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise, though the specific exercise price reflects the current market valuation of the issuer.
Comparison to Industry Standards
- The grant structure follows standard industry practices for board compensation in mid-cap biotech firms.
- Vesting schedules are consistent with typical director retention programs.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of stock options to a director. | 06/11/2026 | Standard alignment of director incentives with company performance. |
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise of these options.
Next Steps
- Vesting of the first 25% of options on October 1, 2026.
Key Dates
| Date | Description |
|---|---|
| 06/11/2026 | Date of grant for the stock options. |
| 10/01/2026 | Initial vesting date for the first tranche of options. |
| 06/11/2036 | Expiration date of the stock options. |
Keywords
Pliant Therapeutics, PLRX, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.